Nitrofurantoin Suspension
NDC Package 43386-450-11
Package Information
Nitrofurantoin suspension is nitrofurantoin oral suspension, USP is specifically indicated for the treatment of urinary tract infections when due to susceptible strains of Escherichia coli, enterococci, Staphylococcus aureus, and certain susceptible strains of Klebsiella and Enterobacter species.Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses.Nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for urinary tract infections. Consequently, many patients who are treated with nitrofurantoin oral suspension, USP are predisposed to persistence or reappearance of bacteriuria. Urine specimens for culture and susceptibility testing should be obtained before and after completion of therapy. If persistence or reappearance of bacteriuria occurs after treatment with nitrofurantoin oral suspension, USP, other therapeutic agents with broader tissue distribution should be selected. In considering the use of nitrofurantoin oral suspension, USP, lower eradication rates should be balanced against the increased potential for systemic toxicity and for the development of antimicrobial resistance when agents with broader tissue distribution are utilized. This formulation utilizes a suspension delivery system. Marketed by Lupin Pharmaceuticals,inc., this product is identified by NDC 43386-450 and is authorized under FDA application ANDA201693.
Identification & Billing
- RxCUI: 311989 - nitrofurantoin 25 MG in 5 mL Oral Suspension
- RxCUI: 311989 - nitrofurantoin 5 MG/ML Oral Suspension
- RxCUI: 311989 - nitrofurantoin 25 MG per 5 ML Oral Suspension
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 43386 - Lupin Pharmaceuticals,inc.
- 43386-450 - Nitrofurantoin
- 43386-450-11 - 1 BOTTLE in 1 CARTON / 230 mL in 1 BOTTLE
- 43386-450 - Nitrofurantoin
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 43386-450-11 identifies a specific commercial package of 1 bottle in 1 carton / 230 ml in 1 bottle of Nitrofurantoin, a human prescription drug labeled by Lupin Pharmaceuticals,inc.. This suspension is formulated for oral use and contains nitrofurantoin as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Lupin Pharmaceuticals,inc. on May 21, 2015. The current certification is valid through December 31, 2027.
How is this Lupin Pharmaceuticals,inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 43386045011. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 230 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.